spiperone has been researched along with Atherosclerotic Parkinsonism in 17 studies
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.
spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with bromocriptine was very effective and five months after the poisoning, MR and (11)C-NMSP/PET images showed improvement, concomitantly with the disappearance of the neuropsychiatric symptoms." | 5.30 | Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning. ( Haida, M; Kozuma, R; Shinohara, Y; Takagi, S; Takahashi, W; Yoshii, F, 1998) |
| "Treatment with bromocriptine was very effective and five months after the poisoning, MR and (11)C-NMSP/PET images showed improvement, concomitantly with the disappearance of the neuropsychiatric symptoms." | 1.30 | Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning. ( Haida, M; Kozuma, R; Shinohara, Y; Takagi, S; Takahashi, W; Yoshii, F, 1998) |
| "Treatment with bromocriptine (5 mg/kg) relieved the parkinsonian symptoms, but the efficacy of this treatment appeared to decrease slightly with time." | 1.28 | Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393. ( Bédard, PJ; Di Paolo, T; Rouillard, C, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (47.06) | 18.7374 |
| 1990's | 9 (52.94) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gnanalingham, KK | 2 |
| Erol, DD | 1 |
| Hunter, AJ | 2 |
| Smith, LA | 2 |
| Jenner, P | 2 |
| Marsden, CD | 2 |
| Curran, EJ | 1 |
| Albin, RL | 1 |
| Becker, JB | 1 |
| Alexander, GM | 1 |
| Schwartzman, RJ | 1 |
| Grothusen, JR | 1 |
| Brainard, L | 1 |
| Gordon, SW | 1 |
| Yoshii, F | 1 |
| Kozuma, R | 1 |
| Takahashi, W | 1 |
| Haida, M | 1 |
| Takagi, S | 1 |
| Shinohara, Y | 1 |
| Borbely, K | 1 |
| Brooks, RA | 1 |
| Wong, DF | 1 |
| Burns, RS | 1 |
| Cumming, P | 1 |
| Gjedde, A | 1 |
| Di Chiro, G | 1 |
| Cadet, JL | 1 |
| Zhu, SM | 1 |
| Lisovoski, F | 1 |
| Haby, C | 1 |
| Borrelli, E | 1 |
| Schleef, C | 1 |
| Revel, MO | 1 |
| Hindelang, C | 1 |
| Zwiller, J | 1 |
| Rouillard, C | 1 |
| Bédard, PJ | 3 |
| Di Paolo, T | 3 |
| Camps, M | 1 |
| Ambrosio, S | 1 |
| Ballarin, M | 1 |
| Reiriz, J | 1 |
| Blesa, R | 1 |
| Mahy, N | 1 |
| Joyce, JN | 1 |
| Marshall, JF | 1 |
| Bankiewicz, KS | 1 |
| Kopin, IJ | 1 |
| Jacobowitz, DM | 1 |
| Ruberg, M | 1 |
| Javoy-Agid, F | 1 |
| Hirsch, E | 1 |
| Scatton, B | 1 |
| LHeureux, R | 1 |
| Hauw, JJ | 1 |
| Duyckaerts, C | 1 |
| Gray, F | 1 |
| Morel-Maroger, A | 1 |
| Rascol, A | 1 |
| Crossman, AR | 1 |
| Clarke, CE | 1 |
| Boyce, S | 1 |
| Robertson, RG | 1 |
| Sambrook, MA | 1 |
| Falardeau, P | 2 |
| Bouchard, S | 1 |
| Boucher, R | 2 |
| Beresford, IJ | 1 |
| Davenport, AP | 1 |
| Sirinathsinghji, DJ | 1 |
| Hall, MD | 1 |
| Hill, RG | 1 |
| Hughes, J | 1 |
| Hantraye, P | 1 |
| Loc'h, C | 1 |
| Tacke, U | 1 |
| Riche, D | 1 |
| Stulzaft, O | 1 |
| Doudet, D | 1 |
| Guibert, B | 1 |
| Naquet, R | 1 |
| Mazière, B | 1 |
| Mazière, M | 1 |
1 review available for spiperone and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
MPTP-induced parkinsonism in the monkey: neurochemical pathology, complications of treatment and pathophysiological mechanisms.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Deoxyglucose; Haplorhini; Humans; Levo | 1987 |
16 other studies available for spiperone and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Benza | 1995 |
Adrenal medulla grafts in the hemiparkinsonian rat: profile of behavioral recovery predicts restoration of the symmetry between the two striata in measures of pre- and postsynaptic dopamine function.
Topics: Adrenal Medulla; Amphetamine; Animals; Apomorphine; Benzazepines; Cerebral Ventricles; Corpus Striat | 1993 |
Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzazepines; Brain; Levodop | 1993 |
Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Benzazepines; Brain; Callith | 1993 |
Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning.
Topics: Basal Ganglia; Bromocriptine; Carbon Monoxide Poisoning; Carbon Radioisotopes; Caudate Nucleus; Cere | 1998 |
NMSP binding to dopamine and serotonin receptors in MPTP-induced parkinsonism: relation to dopa therapy.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adult; Antiparkinson Agents; Binding Sites; Cerebellum | 1999 |
The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat.
Topics: Amphetamine; Animals; Apomorphine; Autoradiography; Biomarkers; Corpus Striatum; Immunohistochemistr | 1992 |
Induction of D2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Blotting, Northern; Corpus Striatum; Dopamine; | 1992 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1990 |
Dopamine D1 and D2 receptors visualized in MPTP treated C57 mice by in vitro autoradiography: lack of evidence of receptor modifications in parkinsonian mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Benzazepines; Brain; Dopamine; Homovanilli | 1989 |
Hemiparkinsonism in a monkey after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is associated with regional ipsilateral changes in striatal dopamine D-2 receptor density.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Carotid Arteries; Corpus Str | 1986 |
Dopaminergic and cholinergic lesions in progressive supranuclear palsy.
Topics: Aged; Brain; Bulbar Palsy, Progressive; Choline O-Acetyltransferase; Corpus Striatum; Dopamine; Fema | 1985 |
Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzaze | 1988 |
Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway--II. Differential localization of dopamine and cholecystokinin receptors.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Autoradiography; Benzazepines; Corpus Striatum; Functional Lat | 1988 |
Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; | 1986 |
"In vivo" visualization by positron emission tomography of the progressive striatal dopamine receptor damage occurring in MPTP-intoxicated non-human primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromine; Corpus Striatum; Disease Models, Ani | 1986 |